drugset / Trial / NCT01376167

Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse

NCT01376167

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this two part study is to test the safety and efficacy of Tafenoquine (with Cholorquine) as a radical cure for Plasmodium vivax (P.vivax) malaria relative to the control Chloroquine.Part 1 aims to select an efficacious and well tolerated dose that can be co-administered with Chloroquine. Part 2 will investigate the safety and efficacy of the selected dose (300 mg tafenoquine) in the treatment and radical cure of Plasmodium Vivax Malaria.

Timeline

Start
2014-04-24
Primary completion
2016-11-18
Completion
2016-11-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Primaquine Small molecule 15 mg
Subject Tafenoquine Small molecule 50 mg
Subject Tafenoquine Small molecule 100 mg
Subject Tafenoquine Small molecule 300 mg
Subject Tafenoquine Small molecule 600 mg
Background Chloroquine Small molecule 600 mg